Stockscreener 앱 받기
77.91
0.21%
0.16
시간 외 거래:
77.72
-0.19
-0.24%
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Pharma stock follows its pipeline story. - AD HOC NEWS
BridgeBio Pharma’s SWOT analysis: stock gains momentum on pipeline strength - Investing.com
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN
Jefferies Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo
BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street - MSN
Responsive Playbooks and the BBIO Inflection - Stock Traders Daily
Enterprise value to revenue forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
Price to book forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
If You Invested $1,000 in Bridgebio Pharma (BBIO) - Stock Titan
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Pharma Raises $933.9 Million Via 7% Convertible Preferred From Sixth Street, HCRx - TradingView
BridgeBio (Nasdaq: BBIO) secures $933.9M in senior convertible preferred equity - Stock Titan
BridgeBio reports kidney function data for acoramidis in ATTR-CM - Investing.com
BridgeBio reports kidney function data for acoramidis in ATTR-CM By Investing.com - Investing.com South Africa
BridgeBio Pharma Announces New Circulation: Heart Failure Analyses Showing Kidney-Protective Effects of Acoramidis in ATTR-CM - Quiver Quantitative
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM - Yahoo Finance
Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026 - Legal Desire Media and Insights
BridgeBio lands $1 billion, mostly from S.F.'s Sixth Street, with three late-stage drugs in hand - The Business Journals
BridgeBio Pharma Announces $1 Billion Convertible Preferred Equity Deal - Moomoo
BridgeBio raises $1 billion in preferred equity - The Pharma Letter
BridgeBio secures up to $1B in preferred equity - MSN
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches - Sixth Street
BridgeBio secures $1 billion in convertible preferred equity By Investing.com - Investing.com South Africa
BridgeBio Pharma | SCHEDULE 13D/A: Others - Moomoo
BridgeBio secures $1 billion in convertible preferred equity - Investing.com
BridgeBio gets $1B from Sixth Street, HCRx for three launches - Stock Titan
BridgeBio gets funding for drug launch; United buys into cell therapy - Yahoo Finance
Global private equity giants continue to increase investments in the innovative pharmaceuticals sector, with firms including KKR injecting $1 billion into BridgeBio. - Moomoo
Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity - 富途牛牛
Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity - Bloomberg.com
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Index - marketscreener.com
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO) - Seeking Alpha
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Growth Benchmark - marketscreener.com
Sector Update: Healthcare - Moomoo
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Growth Benchmark - marketscreener.com
BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial - Moomoo
BridgeBio Pharma, Inc. (BBIO): Investor Outlook Highlights 45.61% Potential Upside Amid Robust Pipeline - DirectorsTalk Interviews
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Growth Benchmark - marketscreener.com
BridgeBio (BBIO) Reports Positive Phase 3 Results for Infigratin - GuruFocus
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Index - marketscreener.com
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia - The Manila Times
BridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasia - Quiver Quantitative
BridgeBio's achondroplasia drug posts NEJM Phase 3 data - Stock Titan
BridgeBio Pharma, Inc. Actuals & Estimates (NASDAQ:BBIO) - TradingView
BridgeBio shareholders approve board changes and equity plan - The Globe and Mail
BBIO Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Pharma Adopts Third Amended 2021 Stock Option and Incentive Plan Following Shareholder Approval - Minichart
BridgeBio Pharma (NASDAQ: BBIO) shareholders approve directors and add 2M plan shares - Stock Titan
BridgeBio Pharma, Inc. Announces the Resignation of Randal W. Scott as Class I Director, Effective as of June 22, 2026 - marketscreener.com
2CL Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Pharma, Inc. Actuals & Estimates (MUN:2CL) - TradingView
Enterprise value to revenue forward of BridgeBio Pharma, Inc. – LS:A2PLX7 - TradingView
Price to book forward of BridgeBio Pharma, Inc. – LS:A2PLX7 - TradingView
Price to book forward of BridgeBio Pharma, Inc. – GETTEX:2CL - TradingView
Enterprise value to EBITDA forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
Price to sales forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
Enterprise value to EBIT forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
BridgeBio Pharma Insider Sold Shares Worth $2,752,270, According to a Recent SEC Filing - marketscreener.com
Price to earnings forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
BridgeBio Pharma director Valantine sells $341,523 in shares By Investing.com - Investing.com Australia
BridgeBio Pharma director Valantine sells $341,523 in shares - Investing.com UK
1.17%
2.48%
자본화:
|
볼륨(24시간):